Elevated Plasma S100B, Psychotic Symptoms, and Cognition in Schizophrenia

Huiqiong Deng, Ramandeep S. Kahlon, Satyajit Mohite, Pooja A. Amin, Giovana Zunta-Soares, Gabriela D. Colpo, Laura Stertz, Gabriel R. Fries, Consuelo Walss-Bass, Jair C. Soares, Olaoluwa O. Okusaga

Research output: Contribution to journalArticlepeer-review

7 Scopus citations


S100B is a calcium binding protein mainly produced by glial cells. Previous studies have shown elevated levels of S100B in patients with schizophrenia. We measured S100B levels in fasting plasma of 39 patients with schizophrenia and 19 adult healthy controls. We used linear regression to compare S100B between patients and controls. In patients only, we also investigated the relationship between S100B levels and psychotic symptoms (assessed by the Positive and Negative Syndrome Scale), and cognitive function (assessed by the NIH Toolbox Cognition Battery), respectively by calculating Pearson’s correlation coefficients. Mean plasma S100B was significantly higher in the patient group than in the control group. There were no significant correlations between plasma S100B and psychotic symptoms or cognition.

Original languageEnglish (US)
Pages (from-to)53-60
Number of pages8
JournalPsychiatric Quarterly
Issue number1
StatePublished - Mar 1 2018
Externally publishedYes


  • Cognition
  • NIH toolbox cognition battery
  • Psychotic symptoms
  • S100B
  • Schizophrenia

ASJC Scopus subject areas

  • Psychiatry and Mental health


Dive into the research topics of 'Elevated Plasma S100B, Psychotic Symptoms, and Cognition in Schizophrenia'. Together they form a unique fingerprint.

Cite this